Patent · US Active

Inhibition of unintended mutations in gene editing

US11840685B2 · kind B2 · utility

0Cited by

0References

13Claims

0Family size

Assignee

SHANGHAITECH UNIVERSITY · CN

Inventors

Jia Chen · Changhua City, TW
Bei Yang · Shiwen, TW
Li Yang · Shanghai, CN
Xingxu Huang · Shanghai, CN
Lijie Wang · 安丰镇, CN

Key dates

Filing date	Jul 11, 2022
Grant date	Dec 12, 2023
Priority date	—
Expiry date	Jul 11, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y305/04005
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Provided are fusion proteins and related molecules useful for conducting base editing with reduced or no off-target mutations. The fusion protein may include a first fragment comprising a nucleobase deaminase or a catalytic domain thereof, a second fragment comprising a nucleobase deaminase inhibitor, and a protease cleavage site between the first fragment and the second fragment. Also provided are improved prime editing systems, including prime editing guide RNA with improved stability.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.